trending Market Intelligence /marketintelligence/en/news-insights/trending/3biMKdExp7dO4mPDbynp0A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Selecta Biosciences prices $70M offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Selecta Biosciences prices $70M offering

Selecta Biosciences Inc. priced a private offering of its common stock to raise about $70 million in gross proceeds, the same day it licensed its immune tolerance platform ImmTOR to Asklepios BioPharmaceutical Inc. for up to $240 million.

The Watertown, Mass.-based biotechnology company offered 45,977,011 units of securities — each made of one share and a warrant to purchase half a share at $1.46 — for $1.5225 apiece to select members of its board and investors, led in the placement by Vivo Capital LLC, Mangrove Partners, EcoR1 Capital LLC, BVF Partners LP and Boxer Capital LLC.

Certain institutional investors chose to receive pre-funded warrants for the company's common stock instead of shares.

The company said the offering would close Dec. 23.

Selecta Biosciences intends to use the net proceeds to fund the ongoing phase 2 Compare trial of its chronic refractory gout therapy SEL-212, as well as for general corporate purposes.

Cantor Fitzgerald & Co. is serving as placement agent for the offering.